$MYOV So Relugolix Phase 3 data met endpoints for SPIRIT 1 and SPIRIT 2 for Endometriosis. Filed NDA for Uterine Fibroids, and is in PDUFA priority reviews for advanced prostate cancer. What's next? I don't see any PR's planned. Are we waiting for news about next steps for SPIRIT 1, SPIRIT 2 and the FDA news for the trials in NDA and PDUFA review?? Does anyone have info on these dates? The only catalyst for movement on my calendar is Q2 2020 Earnings Results on August 4th.